Takeda Pharmaceuticals International Co, 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA.
Novartis Pharma AG, Novartis Campus CH-4056, Basel, Switzerland.
Genomics. 2021 Jan;113(1 Pt 1):420-427. doi: 10.1016/j.ygeno.2020.12.009. Epub 2020 Dec 9.
The ΔΔct method estimates fold change in gene expression data from RT-PCR assay. The ΔΔct estimate aggregates replicates using mean and standard deviation (sd) and is not robust to outliers which are in practice often removed before the non-outlying replicates are aggregated. The alternative of using robust statistics such as median and median absolute deviation (MAD) to aggregate the replicates is not done in practice perhaps because the distribution of a robust ΔΔct estimate based on median and MAD is not straightforward to deduce. We introduce a robust ΔΔct estimate and deduce an approximate distribution for it. Simulations show that when data has outliers, the robust ΔΔct estimate compared to the non-robust ΔΔct estimate leads to significantly reduced confidence interval length and a coverage close to the nominal coverage. The analysis of an RT-PCR data from a Novartis clinical trial demonstrates benefit of a robust ΔΔct estimate.
ΔΔct 方法估计 RT-PCR 测定中基因表达数据的倍数变化。ΔΔct 估计使用平均值和标准差 (sd) 聚合重复项,对离群值不稳健,在实际操作中,通常在聚合无离群值的重复项之前先剔除离群值。聚合重复项时使用中位数和中位数绝对偏差 (MAD) 等稳健统计量的替代方法在实践中并未采用,也许是因为基于中位数和 MAD 的稳健 ΔΔct 估计的分布不容易推断。我们引入了一个稳健的 ΔΔct 估计值,并推导出了它的近似分布。模拟结果表明,当数据存在离群值时,与非稳健的 ΔΔct 估计相比,稳健的 ΔΔct 估计会导致置信区间长度显著缩短,并且覆盖接近名义覆盖。对诺华临床试验的 RT-PCR 数据的分析表明了稳健的 ΔΔct 估计的益处。